BeiGene
456 articles about BeiGene
-
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
11/9/2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the third quarter of 2023 and business highlights.
-
BeiGene to Present at the 2023 Jefferies London Healthcare Conference
11/8/2023
BeiGene, Ltd. announced that the Company will participate in the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 with a fireside chat at 2:00 pm GMT.
-
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
11/7/2023
Adaptive Biotechnologies Corporation today announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies.
-
The abstracts, made available Tuesday ahead of the European Society for Medical Oncology Congress 2023, show strong efficacy data from some promising non-small cell lung cancer treatments.
-
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
10/17/2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by Blinded Independent Central Review (BICR).
-
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
10/17/2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
-
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
10/16/2023
BeiGene, Ltd. announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology Congress 2023.
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
10/13/2023
BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib).
-
ARS Pharmaceuticals, Intarcia Therapeutics and Taysha Gene Therapies this week got stark reminders of the difficulties in getting treatments through the regulator’s approval process.
-
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
9/19/2023
BeiGene, Ltd. announced that the European Commission has approved TEVIMBRA® as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.
-
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
9/19/2023
BeiGene, Ltd., a global biotechnology company, announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA.
-
After facing regulatory roadblocks, Novartis is returning the anti-PD-1 antibody to the cancer-focused biotech, which regains global rights to develop, manufacture and commercialize tislelizumab.
-
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
9/14/2023
Nona Biosciences announced an agreement with BeiGene, Ltd. to expand the companies' discovery strategic collaboration leveraging Nona's proprietary Harbour Mice® platform.
-
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
8/31/2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11th, 2023 with a fireside chat at 9:20 am ET.
-
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
8/2/2023
BeiGene, Ltd., a global biotechnology company, reported financial results from the second quarter of 2023 and business highlights.
-
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
7/21/2023
BeiGene today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
-
This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act
-
Nona Biosciences Announces Business Update of Collaboration on Antibody Drug Conjugate (ADC) with DualityBio
7/13/2023
Nona Biosciences announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors.
-
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
7/12/2023
BeiGene today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy.
-
Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All
7/11/2023
As cell therapies continue to rank among the most expensive of cancer treatments, BeiGene is quietly charting a different path that would enable more equitable access for all.